Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2-Reference-Cited by-同舟云学术

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

Published:2021-04-19 Issue:5 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Painter Wendy P.¹^ORCID,Holman Wayne¹,Bush Jim A.²,Almazedi Firas²,Malik Hamzah²,Eraut Nicola C. J. E.²,Morin Merribeth J.¹,Szewczyk Laura J.¹,Painter George R.³

Affiliation:

1. Ridgeback Biotherapeutics LP, Miami, Florida, USA

2. Covance Clinical Research Unit Limited, Leeds, United Kingdom

3. Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA

Abstract

Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral ribonucleoside analog β- d -N4-hydroxycytidine (NHC; EIDD-1931), has activity against a number of RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and seasonal and pandemic influenza viruses. Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebo-controlled study in healthy volunteers, which included evaluation of the effect of food on pharmacokinetics.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02428-20

Reference11 articles.

1. World Health Organization. 2020. Novel coronavirus (2019-nCoV) situation report 1. World Health Organization, Geneva, Switzerland.

2. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

3. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

4. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection

5. Small-Molecule Antiviral β- d - N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral Infections: Overview with a focus on Prevention of Transmission;International Encyclopedia of Public Health;2025

2. Innovative eco-friendly stability-indicating HPLC-PDA method for simultaneous determination of the emerging antiviral drugs against COVID-19 infection molnupiravir and favipiravir; degradation kinetic studies along with LC-MS based structure elucidation;Microchemical Journal;2024-10

3. MMFA-DTA: Multimodal Feature Attention Fusion Network for Drug-Target Affinity Prediction for Drug Repurposing Against SARS-CoV-2;Journal of Chemical Theory and Computation;2024-09-13

4. An overview of the development of pharmacotherapeutics targeting SARS-CoV-2;Drug Discovery Today;2024-09

5. A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine;Infection and Drug Resistance;2024-09